Case report no 9 recurrence of amyloid in a kidney allograft
1 / 16

Case report no. 9. Recurrence of amyloid in a kidney allograft - PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

Case report no. 9. Recurrence of amyloid in a kidney allograft. Eva Honsová Institute for Clinical and Experimental Medicine Prague, Czech Republic. Clinical history. A 55-year-old man was admitted to the hospital for severe hypertension in 1989.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

Download Presentation

Case report no. 9. Recurrence of amyloid in a kidney allograft

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Case report no. 9.Recurrence of amyloid in a kidney allograft

Eva Honsová

Institute for Clinical and Experimental Medicine

Prague, Czech Republic

Clinical history

  • A 55-year-old man was admitted to the hospital for severe hypertension in 1989.

  • He was well until half a year before when slowly progressing peripheral edema appeared.

  • He didn’t consult his practitioner until he began to suffer from severe headaches with nausea, and blurred vision.

  • 210/130mmHg

  • proteinuria 6g/day, S-Cr level was 296umol/l(3,3mg/dl)

  • there was a 10 times higher level of antibodies against streptolysin O (ASLO).

  • A renal biopsy was performed with clinical diagnosis of postinfectious glomerulonephritis.

Native kidney biopsy sample (from 1989)IF: Igs negative, C3 negat., kappa, lambda: negat.

PAS staining

Congo red

Dg: Amyloidosis of an uncertain type.

  • Extensive searching for some disease associated with amyloidosis

  • 2 nodules in the liver; biopsy unsuccessful

  • No evidence of inflammatory disease

  • No evidence of plasma cell dyscrasia

  • No other disease in addition to DM type II

  • Half a year later: viral respiratory illness; kidney function rapidly declined and hemodialysis was begun.

  • Family medical history

    Both parents dead (mother: 40, abdominal tumor;

    father: 77, DM, IHD; sister: 7, car accident)

    2 children, a son and a daughter: healthy

    No evidence of kidney disease

  • Because of uncertain biological potential of liver lesions, he was not included in the waiting list.

  • Liver masses were stable for 3 years.

  • Patient´s data were reevaluated, 6 years after kidney failure he underwent kidney transplantation.

  • Kidney graft had excellent function for the following 15 years.

  • No kidney graft biopsy was performed.

  • Recently, proteinuria was revealed and a kidney graft biopsy was performed with clinical suspicion of diabetic nephropathy and chronic rejection.

Graft biopsy sampleIF: C4d negative; Igs negative; C3,C1q: negative; kappa:negative; lambda: weakly positive, AA:neg.

GGraft biopsy sample, IF & IH detection fibrinogen A r

Genetic studies were performed and mutation in the fibrinogen gene was confirmed (Glu526Val)

Skin biopsy sample; subsequent IF and IH for fibrinogenA


  • No change in immunosuppressive treatment

  • S-Cr 178μmol/l (2.01mg/dl)

  • PU 3.6g/day

  • DM under control

  • Recently, genetic analysis for his 2 children was offered

Diagnosis of the type of amyloidosis

The most common types: AA+AL

AA (commercial antibodies)

AL(low reactivityof commercial

Abs in paraffinsections)

Hereditary amyloidoses: more frequently recognized, are gaining in clinical importance. Autosomal dominant, variable penetrance, family history is lacking, clinical manifestation at older ages, therefore the correct diagnosis is challenging

Each type requires different therapy, dg must be

based on identification of the protein

Hereditary fibrinogen A amyloidosis

  • Mutation in Fibrinogen Aα-chain gene was first described by Benson et al. in 1993

  • most frequent hereditary amyloidosis in the UK and also in Europe

  • All cases: renal biopsy samples with massive and exclusively glomerular amyloid deposits

  • Median age of presentation: 55years

  • Fibrinogen: produced exclusively by the liver

  • Kidney transplantation alone associated with rapid recurrence of amyloid

  • Liver or combined liver and kidney transplantation

Fascinating story of amyloidosis

  • Not all of patients with „preconditions“ suffer from amyloidosis

  • Genetic factors, different types of degradation

  • Per Westermark: different point of view

  • Comparison with prion diseases: change in the protein structure

  • In experiments, amyloid enhancing factor

  • Amyloid fibrils were identified as the basis of AEF

  • Prion diseases are transmissible by food

Is amyloidosis transmissible?

  • Yes, very probably

  • Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 2009;583:2685-2690.

  • AA amyloidosis is transmissible in several

    animal experimental models

  • AA amyloid can occur in human food

    (ducks, geese: pate de foie gras)

  • AA amyloidosis is transmissible by

    blood monocytes

  • Will we change the management of

    patients at risk of amyloidosis?

ESP Congress, Prague 2012

  • Login